Bessemer Group’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-37
| Closed | – | – | 2695 |
|
|
2025
Q2 | $0 | Hold |
37
| – | – | ﹤0.01% | 2611 |
|
|
2025
Q1 | $0 | Buy |
+37
| New | +$271 | ﹤0.01% | 2697 |
|
|
2022
Q2 | – | Sell |
-81
| Closed | -$3K | – | 2012 |
|
|
2022
Q1 | $3K | Hold |
81
| – | – | ﹤0.01% | 1694 |
|
|
2021
Q4 | $3K | Hold |
81
| – | – | ﹤0.01% | 1732 |
|
|
2021
Q3 | $4K | Hold |
81
| – | – | ﹤0.01% | 1549 |
|
|
2021
Q2 | $5K | Hold |
81
| – | – | ﹤0.01% | 1432 |
|
|
2021
Q1 | $6K | Buy |
+81
| New | +$6.64K | ﹤0.01% | 1377 |
|
|
2019
Q1 | – | Sell |
-416
| Closed | -$40K | – | 1937 |
|
|
2018
Q4 | $40K | Buy |
416
+34
| +9% | +$3.89K | ﹤0.01% | 1371 |
|
|
2018
Q3 | $54K | Buy |
+382
| New | +$59K | ﹤0.01% | 1254 |
|
|
2017
Q4 | – | Sell |
-2,263
| Closed | -$141K | – | 1804 |
|
|
2017
Q3 | $141K | Buy |
+2,263
| New | +$178K | ﹤0.01% | 1124 |
|
|
2017
Q1 | – | Sell |
-32,764
| Closed | -$1.67M | – | 1891 |
|
|
2016
Q4 | $1.67M | Sell |
32,764
-101
| -0.3% | -$4.76K | 0.01% | 564 |
|
|
2016
Q3 | $1.51M | Buy |
32,865
+37
| +0.1% | +$1.51K | 0.01% | 518 |
|
|
2016
Q2 | $989K | Sell |
32,828
-1,021
| -3% | -$34K | 0.01% | 462 |
|
|
2016
Q1 | $1.08M | Buy |
33,849
+1,019
| +3% | +$35.9K | 0.01% | 453 |
|
|
2015
Q4 | $1.91M | Sell |
32,830
-1
| -0% | -$50 | 0.01% | 442 |
|
|
2015
Q3 | $1.39M | Buy |
32,831
+18,703
| +132% | +$1.15M | 0.01% | 493 |
|
|
2015
Q2 | $1.03M | Buy |
14,128
+14,086
| +33,538% | +$906K | 0.01% | 536 |
|
|
2015
Q1 | $2K | Buy |
+42
| New | +$1.81K | ﹤0.01% | 1440 |
|
Other funds holding SAGE
IA
HNB
Bessemer Group's SAGE Position: Q3 2025 in Review
Bessemer Group sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 37 shares.
Bessemer Group first reported a position in SAGE in Q1 2015 and held it in 18 quarters. The position peaked at $1.91M in Q4 2015. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.
- Bessemer Group reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
- Bessemer Group sold 37 Sage Therapeutics shares in Q3 2025.
- Bessemer Group first reported a position in Sage Therapeutics in Q1 2015 and held it in 18 quarters.
- Bessemer Group's Sage Therapeutics position peaked at $1.91M in Q4 2015.
- 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.
Based on Bessemer Group's 13F filing for Q3 2025, filed 5 Nov 2025.